GA

CHFR methylation as novel predictor for chemotherapy response in NSCLC

Therapeutics Award
Funded equally by LUNGevity Foundation and The CHEST Foundation
Johann C. Brandes, MD, PhD
Emory University
Atlanta
GA

The CHFR gene is a gene that has undergone changes in its DNA. Dr. Brandes is studying how the CHFR gene predicts a non-small cell lung cancer patient’s response to chemotherapy.

Key words
Biomarker or biomarker testing
Chemotherapy
Metastatic
Molecular profile or molecular testing
Non-small cell lung cancer (NSCLC)

Targeting CHFR through PARP-inhibition: A novel strategy to overcome taxane resistance in adenocarcinomas of the lung

Therapeutics Award
LUNGevity Foundation/Uniting Against Lung Cancer Research Grant
Johan C. Brandes, MD, PhD
Emory University
Atlanta
GA

The PARP protein is a protein that protects cancer cells from being killed by chemotherapy. Dr. Brandes is determining how drugs that stop the PARP protein can be used for targeted therapy of non-small cell lung cancer.

Key words
Acquired resistance
Adenocarcinoma
Chemotherapy
Non-small cell lung cancer (NSCLC)
PARP
Subscribe to GA